Dechert Advises Mauna Kea Technologies on its Refinancing

Dechert advised Mauna Kea Technologies, inventor of the Cellvizio® endomicroscopy platform, on implementing its refinancing after safeguard proceedings under the classes of affected parties regime.

This particularly innovative transaction, combining a significant reduction of Mauna Kea Technologies’ debt through the leverage of court-supervised collective proceedings under the classes of affected parties regime and several securities issuances providing €6.1 million in new financing, enables the company to focus on growing sales and achieving profitability.

The Dechert team that advised Mauna Kea Technologies included M&A associates Vianney Toulouse, Mathilde Duchamp and Yona Elfassi, under the supervision of M&A partner Alain Decombe.

About Dechert

Dechert is the law firm that helps business leaders lead.

For more than 150 years, we have advised clients on critical issues – from high-stakes litigation to first-in-market transaction structures and complex regulatory matters. Our lawyers in commercial centers worldwide are immersed in the key sectors we serve – financial services, private capital, real estate, life sciences and technology.

Dechert delivers unwavering partnership so our clients can achieve unprecedented results.

Dechert’s Paris office is a key component of the firm's strategy in Europe and is active in antitrust/competition and European law, corporate/M&A, financial services & asset management, financing, intellectual property, labor and employment, litigation and compliance, regulatory and tax.

Dechert’s life sciences team in France represents companies ranging from multinational giants to emerging companies involving all aspects of the life sciences industry, including pharmaceuticals, biotechnology, drug discovery, genomics, biopharmaceuticals, diagnostics, medical devices and health care. We also assist investment funds with life sciences investments. Read more »